PSMA PET Scan-Directed Therapy for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is abiraterone acetate safe for humans?
Abiraterone acetate, used with prednisone, is generally considered safe for treating metastatic castration-resistant prostate cancer, though it can cause side effects like low potassium levels, high blood pressure, fluid retention, and liver issues. In clinical trials, serious side effects were relatively rare.12345
What makes the PSMA PET Scan-Directed Therapy with Abiraterone and Prednisone unique for prostate cancer?
This treatment is unique because it uses PSMA PET scans to guide therapy, allowing for precise targeting of prostate cancer cells, and combines abiraterone and prednisone to inhibit androgen production, which fuels prostate cancer growth. This approach is particularly beneficial for patients with metastatic castration-resistant prostate cancer, as it helps assess treatment response and predict overall survival.678910
What data supports the effectiveness of the drug Abiraterone Acetate in treating prostate cancer?
Who Is on the Research Team?
Evan Yu
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Are You a Good Fit for This Trial?
Men who've had prostate surgery and radiation, with a recent PSA level between 0.2-10 ng/mL that's rising, but no visible metastasis on scans. They should be relatively healthy (ECOG 0 or 1), have certain blood levels within range, and not have other serious illnesses or recent cancers besides non-melanoma skin cancer.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Initial Assessment
Patients undergo fluciclovine or PSMA PET/CT to assess the presence of metastatic disease
Treatment
Patients receive abiraterone acetate and prednisone, with possible lymphadenectomy or radiation therapy for those with ≤ 3 regions of metastatic disease
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
Long-term Follow-up
Annual follow-up visits to monitor long-term outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Abiraterone
- Abiraterone Acetate
- Prednisone
- PSMA PET Scan
Abiraterone is already approved in United States, European Union, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Blue Earth Diagnostics
Industry Sponsor